Brain Implant (BCI) Clinical Trials in 2026

TL;DR: Several companies — Neuralink, Synchron, Paradromics, Precision Neuroscience, Blackrock Neurotech, and Onward Medical — are actively running human clinical trials of brain-computer interfaces (BCIs) for paralysis and speech loss. As of 2026, none of these devices has full FDA marketing approval (PMA). Every implant currently in a human head or spine is part of an investigational study, not an approved medical treatment. Progress is real and measurable, but it is incremental, and the first commercially prescribable BCI is still an industry estimate for 2028–2030.

Brain-computer interface news moves fast, and headlines rarely distinguish between "a company announced a trial," "the FDA cleared a device for testing," and "a treatment is now available." That gap matters enormously to patients and families evaluating whether to apply. This article organizes what has actually been confirmed — by company, by target condition, and by surgical approach — using primary sources, regulatory filings, and clinical trial registrations. Where a claim comes from a press release rather than a peer-reviewed or regulatory source, it's labeled accordingly. Nothing here should be read as medical advice or a promise of outcome.

BCI Trials at a Glance: Company Comparison Table

Roughly 150 people worldwide are estimated to have received some form of implantable BCI as of mid-2026 (Estimated, MIT Technology Review, June 2026). Here's how the major programs compare.

Company	Target condition(s)	Surgical approach	Current stage (2026)	Reliability
Neuralink — PRIME	Cervical spinal cord injury, ALS (quadriplegia)	Penetrating (intracortical threads)	Early feasibility study; 21 participants reported as of Jan 2026	Reported
Neuralink — VOICE	Speech loss (ALS, stroke, SCI, other)	Penetrating	Registered Nov 2025; FDA Breakthrough Device status	Confirmed (registration only)
Synchron — Stentrode / COMMAND	Paralysis (ALS, SCI, stroke)	Endovascular (delivered via jugular vein, no craniotomy)	Feasibility study completed (6 participants, 1-yr follow-up); preparing pivotal trial	Confirmed
Precision Neuroscience — Layer 7	Cortical mapping; motor/communication research	Minimally invasive surface array (thin film, no penetration)	FDA 510(k) cleared for temporary use (up to 30 days); 37 patients tested	Confirmed
Paradromics — Connexus / Connect-One	Speech loss from ALS/motor neuron disease	Penetrating (fully implanted, wireless microelectrode array)	FDA IDE granted Nov 2025; first human implant June 2026 (Michigan)	Confirmed
Blackrock Neurotech — MoveAgain	Paralysis (cursor, keyboard, wheelchair control)	Penetrating (Utah Array-based)	FDA Breakthrough Device designation; trials ongoing	Confirmed (designation, not efficacy)
Onward Medical — ARC-BCI	Spinal cord injury (movement restoration)	Epidural cortical electrodes (non-penetrating) + spinal cord stimulator	7 implants completed by Jan 2026; feasibility study ongoing	Confirmed

Note: "FDA Breakthrough Device" and "FDA 510(k) clearance for a temporary device" are not the same as full marketing approval (PMA) for a permanent implant. Both simply mean the FDA has agreed the device can be studied or used short-term under specific conditions — see the section below on regulatory status.

How the Different BCI Approaches Actually Work

"Brain implant" is often used as a single catch-all term, but the surgical approach determines the risk profile, the signal resolution, and how the device is regulated. There are four broad categories relevant to current trials:

• Penetrating (intracortical): Thin electrode threads or needle arrays are inserted directly into brain tissue, allowing the device to record from individual neurons or small clusters. This gives the highest signal resolution — useful for controlling a cursor or synthesizing speech with fine detail — but it requires open-brain surgery (craniotomy) and carries the highest surgical risk. Neuralink, Paradromics, and Blackrock Neurotech use this approach.
• Endovascular: A stent-like electrode array (Synchron's "Stentrode") is threaded through a blood vessel, similar to a cardiac catheterization, and deployed against the inside wall of a vein sitting over the motor cortex. No skull opening is needed. Signal resolution is lower than penetrating electrodes because the array sits outside brain tissue, but the procedure avoids craniotomy-related risks.
• Minimally invasive surface (epidural/subdural, non-penetrating): A thin electrode film is slid onto or just under the skull without removing bone or piercing brain tissue (Precision Neuroscience's Layer 7) or placed epidurally alongside a separate spinal stimulator (Onward's ARC-BCI). This sits between penetrating and endovascular in both invasiveness and resolution.
• Non-invasive (external): EEG-cap style systems read electrical activity through the scalp with no surgery at all. These aren't part of the implant trials covered in this article, but they remain the lowest-risk, lowest-resolution option and are worth knowing about as a contrast point when a company markets an implant as "necessary."

Company-by-Company Status

Neuralink

Neuralink's PRIME Study (registered as NCT06429735) targets people with cervical spinal cord injury or ALS-related quadriplegia, using the penetrating N1 implant to control a cursor and other digital tools. The first U.S. site was Barrow Neurological Institute in Phoenix (Confirmed, Barrow), later joined by a second U.S. site in Miami (MassDevice). The company reported 13 implants as of October 31, 2025, alongside international expansion into Canada, the UK, and the UAE (Reported, Neuralink). Participant counts were reported at 12 in September 2025 and 21 by January 2026 (Reported). A second program, VOICE (Neuralink, registered as NCT07224256 in November 2025), targets speech restoration for ALS, stroke, and spinal cord injury and holds FDA Breakthrough Device status. A third initiative, Blindsight, also holds FDA Breakthrough status and aims at vision restoration — but any specific patient-count targets tied to Blindsight are the company's stated goals, not confirmed enrollment figures, and should not be read as fact.

Synchron

Synchron's endovascular Stentrode avoids open-brain surgery entirely. Its U.S. COMMAND early feasibility study enrolled six participants and reported no serious device-related adverse events at the one-year mark, with the device successfully deployed and capturing motor-related brain signals in all six cases (Confirmed, Synchron/BusinessWire). Company statements around its November 2025 Series D funding round put the cumulative number of Stentrode implants across U.S. and Australian trials at roughly 10, though the exact figure varies slightly by source and by date cited (Reported, Synchron Series D announcement). That $200 million raise is earmarked to fund a pivotal trial aimed at securing the first FDA approval (PMA) for an implantable communication BCI (Confirmed, Tech Times).

Precision Neuroscience

Precision Neuroscience's Layer 7 Cortical Interface is a flexible, thin-film array that sits on the brain's surface without penetrating tissue, distinguishing it from Neuralink's and Paradromics' needle-based systems. In April 2025, the FDA cleared Layer 7 under the 510(k) pathway for temporary use of up to 30 days — a materially different, lower bar than full PMA approval for a permanent device (Confirmed, MassDevice). The company reports having tested the device in 37 patients across partner institutions.

Paradromics

Paradromics' Connexus system is a fully implanted, wireless microelectrode array aimed primarily at restoring communication for people with severe motor speech loss. The FDA granted an Investigational Device Exemption for the Connect-One study in late 2025 (Confirmed, BioSpace), with clinical sites at UC Davis, Massachusetts General Hospital, and the University of Michigan. The first human implant took place at Michigan Medicine in June 2026, in a patient with motor neuron disease affecting her ability to speak (Confirmed, Michigan Medicine).

Blackrock Neurotech

Blackrock Neurotech, whose Utah Array hardware underpins much of the academic BCI research literature over the past two decades, received FDA Breakthrough Device designation for its MoveAgain system, intended to let people with paralysis control a cursor, keyboard, or wheelchair (Confirmed, Blackrock Neurotech). Breakthrough designation speeds up FDA review interactions; it is not itself evidence of efficacy or a marketing approval.

Onward Medical

Onward's approach differs from the others in that it pairs a non-penetrating epidural cortical implant with a separate spinal cord stimulator, aiming to reconnect the "intention to move" signal in the brain with a stimulated spinal cord below a spinal cord injury. Procedures have been performed at CHUV Lausanne in Switzerland under neurosurgeon Jocelyne Bloch. The company reported its seventh implant by January 2026 (Confirmed, BioSpace). Note that this trial runs in Europe, not under an FDA pathway.

Deep Dive: What Really Happened With Neuralink's First Patient

No single case has been more scrutinized — or more misrepresented in casual retellings — than that of Neuralink's first PRIME participant, Noland Arbaugh, implanted in late January 2024 at Barrow Neurological Institute (Confirmed). This case is worth unpacking carefully because it illustrates both a real limitation of early-stage implants and a real example of how software can partially compensate for hardware problems.

Within roughly a month of implantation, a number of the device's ultra-thin recording threads pulled back, or "retracted," from the surface of the brain — Neuralink's own blog post describes this only in general terms, without citing an exact percentage (Confirmed, Neuralink). The more specific figure that circulated widely — that roughly 85% of the implanted threads were lost, leaving about 15% still functional — came from the patient himself in interviews, reported by outlets including the Wall Street Journal (Reported — this is the patient's own characterization, not an official company figure, attributed accordingly, PopSci, CBS News).

What happened next is the part often left out of headlines. Neuralink did not perform a second brain surgery to fix the retracted threads. Instead, engineers modified the software: they changed the algorithm used to record and interpret signals from the remaining electrodes, improved the decoding model, and adjusted the user interface. According to the company, this software-only intervention restored Arbaugh's cursor-control performance (measured in bits per second) to a level that matched, and eventually exceeded, his pre-retraction baseline (Confirmed, company statement). It's important to be precise about what that recovery means: the physical loss of contact between the retracted threads and brain tissue was not reversed. What improved was performance drawn from the electrodes that remained functional — a software-driven workaround, not a hardware fix, and not a "cure" for the underlying mechanical issue. Independent commentary at the time noted that this kind of setback, and Neuralink's public disclosure of it, was arguably useful for the broader field precisely because it was made visible rather than hidden (Forbes commentary).

For later participants, Neuralink reportedly changed its surgical protocol, inserting threads deeper into brain tissue (roughly 3–5mm initially, moved to around 8mm) to reduce the chance of retraction (Reported, Wall Street Journal). The second PRIME participant, implanted in August 2024, reportedly showed no thread retraction (Reported, Neuralink). Separately, Reuters reported — citing anonymous sources — that Neuralink may have observed similar retraction issues in earlier animal studies before the human trial began; this claim has not been independently confirmed by Neuralink and should be read as an unverified, sourced allegation rather than an established fact.

Arbaugh has continued to use the device and gave a public 28-month update at a robotics summit in May 2026, describing his ongoing experience directly (Confirmed, his own talk, Tech Times). One phrase worth flagging for accuracy: Neuralink's software updates are the result of engineers iteratively modifying and redeploying code based on observed performance — this is not the same as the implant "teaching itself" or "self-updating" autonomously, and coverage that implies otherwise overstates the current technology.

How to Actually Join a Trial (and Why the Public Registry Matters)

Every legitimate BCI trial in the U.S. must be registered on ClinicalTrials.gov — this isn't optional marketing transparency, it's a federal legal requirement under the FDA Amendments Act of 2007 (FDAAA 801), intended to protect research subjects and keep trial data auditable. If a program you're reading about doesn't have a public registry number, treat that as a red flag rather than a sign of exclusivity.

Neuralink's process is the most publicly documented: applicants start with an online questionnaire through the Neuralink Patient Registry (roughly 45–60 minutes), followed by consent to a medical-records review, a preliminary eligibility check, and then formal screening. Published PRIME eligibility criteria include:

• Age 22 or older
• Severe quadriplegia caused by cervical spinal cord injury, or ALS with no meaningful improvement in over a year
• Little to no useful hand/arm movement
• Life expectancy of at least 12 months
• Ability to communicate in English
• Living reasonably near a trial site
• A reliable caregiver available for the study's roughly six-year commitment

Common exclusions include high surgical risk, an existing active implanted device, BMI over 40, uncontrolled epilepsy or diabetes, any condition requiring future MRI scans, and immunosuppression. For the other companies covered here, the practical path is the same in spirit: check the relevant clinicaltrials.gov listing, then contact the named academic site directly — for example, UC Davis, Massachusetts General Hospital, or University of Michigan for Paradromics' Connect-One, or CHUV Lausanne for Onward's ARC-BCI (note this is a European site, outside FDA jurisdiction).

On cost: sponsors typically cover surgery and trial-related medical management for approved U.S. participants, but details around travel reimbursement and ancillary costs vary by protocol and were inconsistent across sources reviewed for this article — treat any specific cost claim as something to confirm directly with the trial coordinator before assuming it applies to you.

Risks and Limitations Worth Weighing

None of this is risk-free, and no responsible source should suggest otherwise. Some points to weigh:

Risk category	What it means in practice
Surgical risk	Craniotomy-based implants carry standard neurosurgical risks — infection, bleeding, and general anesthesia risk — though endovascular and minimally invasive approaches aim to reduce this.
Device/hardware risk	Electrode threads or arrays can shift, retract, or degrade over time, as seen in Neuralink's first case; long-term biocompatibility over years to decades is still being studied.
Unknown durability	Most trials have follow-up windows measured in months to a few years. How these devices perform — and what happens if a company changes, pauses, or discontinues support — over a 10+ year horizon is genuinely unknown.
Explant and removal	What removal involves, and whether it's routine or complex, differs by device type and hasn't been extensively documented publicly for most of these programs.
Access and burden	Eligibility criteria are narrow, sites are few, and participation can require a multi-year commitment and a dedicated caregiver — a real burden that isn't always visible in headline coverage.
Data and privacy	Neural signal data is sensitive by nature; how it's stored, who can access it, and what happens to it after a trial ends are reasonable questions to ask any trial coordinator directly.

Frequently Asked Questions

Is any brain implant BCI actually approved by the FDA in 2026?

No. As of 2026, no implantable BCI for paralysis or speech restoration has received full FDA marketing approval (PMA). Every device covered in this article is either in an early feasibility study, a pivotal trial, or operating under a temporary-use clearance (Confirmed).

What's the difference between "FDA cleared for a trial" and "FDA approved"?

An Investigational Device Exemption (IDE) or Breakthrough Device designation means the FDA has agreed a device can be tested in humans under a controlled study — it says nothing about whether the device works or is safe for general use. Full approval (a Premarket Approval, or PMA) is a separate, much higher bar that comes after a device has completed pivotal trials and demonstrated safety and effectiveness. A 510(k) clearance, used for Precision Neuroscience's temporary device, is a third, distinct pathway typically reserved for devices similar to something already on the market.

How many people worldwide currently have a BCI implant?

Industry estimates put the number at roughly 150 people globally as of mid-2026, across all companies and trial types combined (Estimated, MIT Technology Review).

Did Neuralink's first patient's implant fail?

Part of the hardware did — a number of recording threads retracted from the brain within about a month. The patient's own account puts the loss at roughly 85% of threads. However, Neuralink says a software update restored and later exceeded his original cursor-control performance using the remaining functioning electrodes. That's a partial hardware setback with a software-driven functional recovery — not a full device failure, and not evidence the underlying mechanical issue was fixed.

Can I sign up for one of these trials right now?

You can apply through official channels — the Neuralink Patient Registry, or by contacting the named academic sites for Synchron, Paradromics, Precision Neuroscience, Blackrock, or Onward directly. Eligibility is narrow (specific diagnoses, severity thresholds, and site proximity requirements), and being accepted into screening does not guarantee enrollment.

Are these the same as the non-invasive EEG headsets sold for meditation or gaming?

No. Consumer EEG headsets read electrical signals through the scalp with no surgery and far lower resolution. The devices in this article are surgically implanted or delivered via catheter, and all currently require a formal clinical trial for access.

When will an implantable BCI actually be available as a real treatment?

Industry estimates suggest the first commercially prescribable implantable BCI could arrive between 2028 and 2030, most likely for communication or motor-control applications, pending successful pivotal trials and FDA approval. This is a projection, not a confirmed timeline, and could shift in either direction.

Conclusion

The honest summary of where BCI trials stand in 2026 is this: real, verifiable progress is happening across multiple companies and multiple surgical approaches, participant numbers are growing year over year, and at least one program (Synchron) has stated an explicit goal of reaching the first FDA-approved implantable communication BCI. At the same time, every implant currently active in a human patient is part of an investigational study. No implantable BCI for paralysis or speech loss is an approved medical treatment today, and the field's own timelines put the first prescribable product several years out. Cases like Neuralink's first patient show both the real risks of early-stage hardware and the genuine, if partial, ways software can compensate — neither the optimistic nor the alarmist framing alone captures what actually happened.

Disclaimer: This article is for general informational purposes only and does not constitute medical advice, a treatment recommendation, or an endorsement of any company, device, or trial. Brain-computer interface implants discussed here are investigational and have not been approved by the FDA for general clinical use. Anyone considering participation in a clinical trial should consult their own physician and speak directly with the trial's official coordinators about risks, eligibility, and current protocol details before making any decision.